Interviews

Ha Kung Wong, JD, partner at Fitzpatrick, Cella, Harper and Scinto, discusses the Trump administration's proposal to allow importation of drugs, including biologics.

Ha Kung Wong, JD, partner at Fitzpatrick, Cella, Harper and Scinto, discusses how the FDA and Federal Trade Commission (FTC) might work together to address anticompetitive behavior in the biosimilars marketplace.

Ha Kung Wong, JD, partner at Fitzpatrick, Cella, Harper and Scinto, discusses key features of the Biosimilar Action Plan.

Vivian Bykerk, MD, associate attending rheumatologist at the Hospital for Special Surgery, associate professor of medicine at Weill Cornell Medical College, discusses switching patients to biosimilars.

Vivian Bykerk, MD, associate attending rheumatologist at the Hospital for Special Surgery, associate professor of medicine at Weill Cornell Medical College, describes her level of comfort with using biosimilars in practice.

Vivian Bykerk, MD, associate attending rheumatologist at the Hospital for Special Surgery, associate professor of medicine at Weill Cornell Medical College, explains why treating rheumatoid arthritis (RA) early is crucial.

Stephen Marmaras, director of policy and advocacy for the Global Healthy Living Foundation, discusses the burden of high-cost biologics.

Stephen Marmaras, director of policy and advocacy for the Global Healthy Living Foundation, discusses the challenge of prior authorizations.

Vivian Bykerk, MD, associate attending rheumatologist at the Hospital for Special Surgery, associate professor of medicine at Weill Cornell Medical College, discusses how cost affects patient access to biologic therapies.

Vivian Bykerk, MD, associate attending rheumatologist at the Hospital for Special Surgery, associate professor of medicine at Weill Cornell Medical College, provides an overview of what patients should know about biologic therapies versus conventional disease-modifying anti-rheumatic drugs.

Mark Cziraky, PharmD, CLS, describes what he sees as the future of the biosimilars space.

Cate Lockhart, PharmD, PhD, describes how the Biologics and Biosimilars Collective Intelligence Consortium (BBCIC) was formed.

Tahir Amin, DipLP, co-founder and director of intellectual property of Initiative for Medicines, Access, and Knowledge, discusses how his organization has helped bring down drug costs.

Tahir Amin, DipLP, co-founder and director of intellectual property of Initiative for Medicines, Access, and Knowledge, discusses the role of patent opposition in giving patients access to high-cost drugs.

Tahir Amin, DipLP, co-founder and director of intellectual property of Initiative for Medicines, Access, and Knowledge, discusses his organization's ongoing work in challenging drug patents.

Vivian Bykerk, MD, associate attending rheumatologist at HSS, associate professor of medicine at Weill Cornell Medical College discusses new treatments in inflammatory disease.

Cate Lockhart, PharmD, PhD, discusses the similarities and differences in the biosimilar and generic markets.

Anne Bass, MD, rheumatologist at the Hospital for Special Surgery and professor of clinical medicine at Weill Cornell Medicine, discusses the potential for biosimilars to increase access to care.

Cate Lockhart, PharmD, PhD, discusses whether her work with the BBCIC will help encourage patient acceptance of biosimilars.

Anne Bass, MD, rheumatologist at the Hospital for Special Surgery and professor of clinical medicine at Weill Cornell Medicine, talks about some emerging treatments in inflammatory disease.

Anne Bass, MD, rheumatologist at the Hospital for Special Surgery and professor of clinical medicine at Weill Cornell Medicine, discusses how rheumatologists treat musculoskeletal adverse events caused by immune checkpoint inhibitors.

Cate Lockhart, PharmD, PhD, discusses when she believes the industry will start seeing biosimilars driving down cost of drugs.

Cate Lockhart, PharmD, PhD, explains the similarities and differences between generics and biosimilars.

Sheila Frame, vice president and head of biopharmaceuticals, North America, at Sandoz, explains what about biosimilars excites the company.

Sheila Frame, vice president and head of biopharmaceuticals, North America, at Sandoz, discusses how physicians' attitudes toward biosimilars have changed.

Mark Cziraky, PharmD, CLS, explains the role of health economics and outcomes research in a payer’s decision to potentially adopt a biosimilar.

Sheila Frame, vice president and head of biopharmaceuticals, North America, at Sandoz, discusses patient concerns about switching to a biosimilar.

Sheila Frame, vice president and head of biopharmaceuticals, North America, at Sandoz, explains how the Biologics Price Competition and Innovation Act (BPCIA) has impacted the industry.

Mark Cziraky, PharmD, CLS, explains why real-world data are key in the biosimilars marketplace.

Sheila Frame, vice president and head of biopharmaceuticals, North America, at Sandoz, discusses policy challenges related to biosimilars.